顺铂、博来霉素和丝裂霉素-C用于复发性子宫颈鳞状细胞癌患者的II期评估。

A phase II evaluation of cisplatin, bleomycin, and mitomycin-C in patients with recurrent squamous cell carcinoma of the cervix.

作者信息

Hoffman M S, Kavanagh J J, Roberts W S, LaPolla J P, Fiorica J V, Hewitt S, Cavanagh D

机构信息

Department of Obstetrics and Gynecology, H. Lee Moffitt Cancer Center, University of South Florida College of Medicine, Tampa 33612.

出版信息

Gynecol Oncol. 1991 Feb;40(2):144-6. doi: 10.1016/0090-8258(91)90106-f.

DOI:10.1016/0090-8258(91)90106-f

PMID:1707024

Abstract

Cisplatin, bleomycin, and mitomycin-C were used to treat 25 patients with recurrent squamous cell carcinoma of the cervix. Six patients had a partial response, yielding a total response rate of 27%. Nine patients had stable disease. The median survival for the whole group was 30 weeks. The median survival for responders was 32 weeks. The median progression free interval for the whole group was 12 weeks and the median progression-free free interval for responders was 14 weeks. The toxicities noted were primarily nausea, vomiting, and myelosuppression. The combination of cisplatin, bleomycin, and mitomycin-C has modest effectiveness in the treatment of recurrent squamous cell carcinoma of the cervix, but represents no improvement over single-agent chemotherapy.

摘要

顺铂、博来霉素和丝裂霉素-C用于治疗25例复发性宫颈鳞状细胞癌患者。6例患者部分缓解，总缓解率为27%。9例患者病情稳定。全组的中位生存期为30周。缓解者的中位生存期为32周。全组的中位无进展生存期为12周，缓解者的中位无进展生存期为14周。观察到的毒性主要为恶心、呕吐和骨髓抑制。顺铂、博来霉素和丝裂霉素-C联合用药在治疗复发性宫颈鳞状细胞癌方面有一定疗效，但并不比单药化疗有改善。